Table 5.
Adjusted excess hazard ratios among 64,836 HIV-infected patients initiating combination antiretroviral therapy, the China National Free Antiretroviral Treatment Program 2003 – 2009†
| eHR (95% CI) | |
|---|---|
| Calendar period of follow up | |
| 2003–2004 | 1.27 (1.11 – 1.45) |
| 2005–2007 | 1.16 (1.09 – 1.23) |
| 2008–2009 | 1.00 |
| Age (years) | |
| ≥45 | 1.63 (1.47 – 1.82) |
| 30–44 | 1.27 (1.15 – 1.40) |
| 18–29 | 1.00 |
| Gender | |
| Men | 1.37 (1.29 – 1.45) |
| Women | 1.00 |
| HIV exposure | |
| Blood transfusion/former plasma donation | 0.98 (0.89 – 1.08) |
| Intravenous drug use | 1.72 (1.57 – 1.88) |
| Sexual transmission | 1.00 |
| Area of residence | |
| Rural | 1.17 (1.08 – 1.26) |
| Urban | 1.00 |
| Health care setting | |
| General hospital | 0.85 (0.76 – 0.95) |
| Infectious diseases hospital | 0.34 (0.30 – 0.40) |
| Centers for diseases control clinic | 0.89 (0.81 – 0.97) |
| Health care under township level/prison hospital | 1.00 |
| CD4 count (cells/μL) | |
| 0–49 | 9.92 (8.59 – 11.44) |
| 50–199 | 4.08 (3.55 – 4.70) |
| 200–349 | 1.82 (1.56 – 2.11) |
| ≥350 | 1.00 |
| Number of baseline symptom | |
| ≥4 | 2.10 (1.91 – 2.31) |
| 2–3 | 1.65 (1.49 – 1.82) |
| 1 | 1.35 (1.19 – 1.52) |
| 0 | 1.00 |
| Initiation regimen‡ | |
| NVP+3TC+AZT | 1.11 (0.94 – 1.31) |
| NVP+3TC+D4T | 1.09 (0.93 – 1.27) |
| NVP+DDI+AZT | 1.37 (1.17 – 1.62) |
| NVP+DDI+D4T | 0.97 (0.80 – 1.17) |
| Other regimens | 1.24 (1.00 – 1.54) |
| EFV+3TC+D4T | 1.20 (1.00 – 1.43) |
| EFV+3TC+AZT | 1.00 |
†
Estimates from one model including all characteristics listed in table
‡
NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz.